China Biologic Products Executives
China Biologic employs about 2.2 K people. The company is managed by 14 executives with a total tenure of roughly 152 years, averaging almost 10.0 years of service per executive, having 160.43 employees per reported executive. Analysis of China Biologic's management performance can provide insight into the firm performance.
David Gao Chairman Chairman of the Board and Presidentident, CEO |
Xiaoying Gao Chairman Executive Chairman, CEO and Pres |
China |
China Biologic Management Team Effectiveness
The company has return on total asset (ROA) of 5.82 % which means that it generated a profit of $5.82 on every $100 spent on assets. This is normal as compared to the sector avarege. Similarly, it shows a return on stockholder's equity (ROE) of 9.25 %, meaning that it created $9.25 on every $100 dollars invested by stockholders. China Biologic's management efficiency ratios could be used to measure how well China Biologic manages its routine affairs as well as how well it operates its assets and liabilities.China Biologic Workforce Comparison
China Biologic Products is number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 34,180. China Biologic holds roughly 2,246 in number of employees claiming about 7% of stocks in Biotechnology industry.
The company has Profit Margin (PM) of 29.04 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 37.26 %, which suggests for every 100 dollars of sales, it generated a net operating income of $37.26. China Biologic Notable Stakeholders
A China Biologic stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as China Biologic often face trade-offs trying to please all of them. China Biologic's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting China Biologic's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
David Gao | Chairman of the Board and Presidentident, CEO | Profile | |
Xiaoying Gao | Executive Chairman, CEO and Pres | Profile | |
Ming Yang | CFO | Profile | |
Min Fang | Director | Profile | |
Joseph Chow | Independent Director | Profile | |
Xiaosheng Shao | Independent Director | Profile | |
Zhijun Tong | Independent Director | Profile | |
Yungang Lu | Independent Director | Profile | |
Wenfang Liu | Independent Director | Profile | |
Wai Yeung | Independent Director | Profile | |
David Li | Director | Profile | |
Zhijing Liu | Corporate VP | Profile | |
Gang Yang | Corporate VP and General Manager of Guizhou Taibang | Profile | |
Ming Yin | Sr. Corporate VP and Corporate Secretary | Profile |
China Biologic Workforce Analysis
Traditionally, organizations such as China Biologic use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare China Biologic within its industry.China Biologic Manpower Efficiency
Return on China Biologic Manpower
Revenue Per Employee | 233.5K | |
Revenue Per Executive | 37.5M | |
Net Income Per Employee | 67.8K | |
Net Income Per Executive | 10.9M | |
Working Capital Per Employee | 132.4K | |
Working Capital Per Executive | 21.2M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in China Stock
If you are still planning to invest in China Biologic Products check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the China Biologic's history and understand the potential risks before investing.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |